2425 55th Street, Suite 210 Boulder, CO 80301 303-420-4420

Bolder BioTechnology Announces Presentation at Radiation Injury Treatment Conference

Boulder, Colorado – September 6, 2018 – Bolder BioTechnology, Inc. announced today that Dr. Joe Cox, Company President, gave an oral presentation at the “Growth Factors and Other Cytokines for Treatment of Injuries During a Radiation Public Health Emergency” meeting held August 30, 2018 at the National Institute of Allergy and Infectious Diseases Conference Center, 5601 Fishers Lane, Rockville, Maryland. The title of Dr. Cox’ presentation was “BBT-059, a Long-Acting Interleukin-11 Analog for Hematopoietic ARS.” The meeting was jointly sponsored by the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Radiation and Nuclear Countermeasures Program, and the Radiation Injury Treatment Network.

About Acute Radiation Syndrome
Acute Radiation Syndrome (ARS) is a collection of illnesses that occurs following exposure to high doses of ionizing radiation within a short period of time, such as might occur following an accident at a nuclear power plant or detonation of a nuclear weapon. Bone marrow, which is where most new blood cells are formed, is one of the most radiation-sensitive tissues, and subjects acutely exposed to high doses of radiation typically develop bone marrow aplasia and severe neutropenia (low numbers of neutrophils) and thrombocytopenia (low numbers of platelets) within days to weeks of exposure (referred to as the hematopoietic acute radiation syndrome). Many subjects die during this time period from infections (due to a lack of neutrophils) or from uncontrolled bleeding (due to a lack of platelets).

About BBT-059
BBT-059 is a long-acting IL-11 analog that stimulates production of platelets, a type of blood cell important for clotting. BBT-059 has been selectively modified with the polymer polyethylene glycol at a unique site in the protein, which allows the protein to last longer in patients, reducing the need for frequent administration and increasing the protein’s ability to stimulate long-lasting production of platelets.

Government Support
The studies described in the presentation were funded by grants AI107340, AI088928, and CA084851 awarded by the National Institute of Allergy and Infectious Diseases and the National Cancer Institute of the National Institutes of Health.

About Bolder BioTechnology
Bolder BioTechnology, Inc. is a private company that uses advanced protein engineering and bioconjugation technologies to create easier to use, safer and more cost-effective human protein pharmaceuticals. For additional information about Bolder BioTechnology, please visit www.bolderbio.com.

Media Contact: Joe Cox, Ph.D., President
Phone: (303) 420-4420 x202; Email: jcox@bolderbio.com